Clinical trial NCT00039585 (phase 2, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
             cancer OR

          -  Histologically confirmed ovarian low malignant potential tumor with invasive
             recurrence

          -  Relapsed after and/or refractory to platinum- and taxane-based chemotherapy

          -  Patients in first relapse after a disease-free interval of more than 1 year are
             eligible

          -  Measurable disease outside prior radiation field

          -  Availability of a sentinel lesion that is adequate for core biopsy through
             percutaneous biopsy or simple laparoscopic means

          -  Patients with clinical evidence of CNS involvement (abnormal clinical examination)
             must have a negative CT scan with contrast or MRI of the brain

          -  No large volume ascites or pleural effusion

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Hemoglobin at least 9.0 g/dL (independent of epoetin alfa or transfusion)

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  Transaminases no greater than 2.5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Cardiovascular:

          -  No myocardial infarction or unstable dysrhythmia within the past 6 months

          -  No congestive heart failure (CHF), including CHF that may be compensated with
             furosemide

        Other:

          -  No other invasive malignancy within the past 5 years except noninvasive nonmelanoma
             skin cancer

          -  No active infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after study completion

          -  Concurrent residual, stable, grade 2 or lower peripheral neuropathy allowed at the
             discretion of the principal investigator (PI)

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior signal transduction therapy

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or carboplatin)

        Endocrine therapy:

          -  At least 4 weeks since prior hormonal therapy

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  Recovered from prior anticancer therapy

          -  At least 1 week since prior antibiotics

          -  No more than 4 prior anticancer regimens

          -  No concurrent ketoconazole, itraconazole, erythromycin, or clarithromycin

          -  No concurrent therapeutic warfarin

               -  Patients who can be safely converted over to low molecular weight heparin are
                  eligible

          -  No concurrent grapefruit or grapefruit juice

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent alternative or complementary therapies or over-the-counter agents unless
             approved by the PI

          -  Concurrent medications that may alter the metabolism of imatinib mesylate and lead to
             potential toxicity are allowed at the discretion of the PI